Thoughts on SUDA’s proprietary OroMist® oro-mucosal technology being a possible contender?
"Currently, MMV is working to improve the formulation of DSM265 and to identify the optimal partner drug to achieve a single dose treatment of P. falciparum malaria.”
https://www.id-hub.com/2019/03/11/experimental-antimalarial-shows-promise-human-challenge-study/